Shingo Eikawa

Icahn School of Medicine at Mount Sinai — United States

Immunology and Microbiology · Life Sciences

13h-index1.3kcitations43works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(18), Cancer Immunotherapy and Biomarkers(16), T-cell and B-cell Immunology(9), Immune Cell Function and Interaction(6), Metabolism, Diabetes, and Cancer(5)

Publications43 total

Abstract B026: αvβ5 Integrin serves as a tumor-specific marker for immunosuppressive regulatory T cells in pancreatic cancer
Cancer Research·2024
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer
Journal for ImmunoTherapy of Cancer·2023· 14 citedOpen Access
Tumor-resident regulatory T cells in pancreatic cancer express the αvβ5 integrin as a targetable activation marker
2023· 4 citedOpen Access
Dysfunction of CD8 + PD-1 + T cells in type 2 diabetes caused by the impairment of metabolism-immune axis
Scientific Reports·2020· 56 citedOpen Access
Abstract 3381: Identifying tumor antigen-specific CD4+ T cell dysfunctional states by single cell transcriptomics in immunotherapy-treated cancer patients
Cancer Research·2020
Berberine improved experimental chronic colitis by regulating interferon-γ- and IL-17A-producing lamina propria CD4+ T cells through AMPK activation
Scientific Reports·2019· 77 citedOpen Access
Abstract 4558: Mapping tolerized T cell states to exhaustion phenotypes in NSCLC
Cancer Research·2019
Abstract 4558: Mapping tolerized T cell states to exhaustion phenotypes in NSCLC
Tumor Biology·2019Open Access
メトフォルミンは,CD11b + 細胞による骨肉腫の増殖阻害を誘導する:骨髄性細胞の代謝再プログラム化と抗腫瘍効果の示唆
2019
Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects
International Immunology·2018· 115 citedOpen Access
[Metabolic Competition in Tumor Microenvironment].
PubMed·2017· 3 cited
Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug
EBioMedicine·2017· 145 citedOpen Access
Abstract 5592: Metformin improves immune function of exhausted peripheral CD8+ T cells derived from cancer patients
Cancer Research·2017· 4 cited
Metformin-dependent metabolic reprogramming contributes to efficient anti-tumor immunity.
PubMed·2017· 2 cited
がん免疫療法 III.特論 メトホルミンによる代謝改変と抗腫瘍免疫応答
日本臨床·2017
Attenuation of CD4+CD25+ regulatory T cells in the tumor microenvironment by metformin, a type 2 diabetes drug
Okayama University Scientific Achievement Repository (Okayama University)·2017
Study about the Efficacy of Metformin to Immune Function in Cancer Patients.
PubMed·2016· 5 cited
Abstract 4865: Metformin improves multiple cytokine producing ability of exhausted peripheral CD8+ T cells of cancer patients
Cancer Research·2016
The induction of antigen-specific CTL by in situ Ad-REIC gene therapy
Gene Therapy·2016· 5 cited
CD8+TILのメトホルミン誘発,代謝性リプログラミングは活性酸素種(ROS)を必要とする
日本免疫学会総会・学術集会記録·2016
page 1 of 3Next →

Frequent Co-authors

Heiichiro Udono(21), Eiichi Nakayama(17), Akiko Uenaka(14), Mikio Oka(14), Midori Isobe(13), Yoshihiro Ohue(12), Yuki Kunisada(8), Yu Mizote(8), Takenori Uehara(6), Minoru Fukuda(5), Mikako Nishida(4), Koji Kurose(4), Kazuhiro Kakimi(4), Sacha Gnjatic(4), Hirofumi Matsumoto(4), Shusaku Mizukami(3), Chihiro Yamazaki(3), Nahoko Tomonobu(3), Toshifumi Ozaki(3), Kenta Kitaoka(3)